Plasma Proneurotensin and Incidence of Diabetes, Cardiovascular Disease, Breast Cancer, and Mortality
Plasma Proneurotensin and Incidence of Diabetes, Cardiovascular Disease, Breast Cancer, and Mortality
复制标题
DOI：
10.1001/jama.2012.12998
复制
发表时间：
2012-10-10
影响因子：
120.7
通讯作者：
Orho-Melander, Marju
中科院分区：
文献类型：
--
作者：
Melander, Olle;Maisel, Alan S.;Orho-Melander, Marju
背景神经降压素在实验环境中调节饱腹感和乳腺癌的生长，但对其在人类乳腺癌或心脏代谢性疾病发生中的作用知之甚少。目的测试空腹血浆中神经降压素前体激素原神经降压素的稳定的117个氨基酸片段的浓度是否与糖尿病、心血管疾病、乳腺癌和死亡率的发生有关。设计、设置和参与者对1991-1994年基于人群的Malmo饮食和癌症研究基线检查的4632名参与者的血浆前神经降压素进行测定。结果总体而言，前神经降压素(每增加1个SD的危险比[HR])与糖尿病(142个事件；HR，1.28；95%CI，1.09-1.50；P=.003)、心血管疾病(519个事件；HR，1.17；95%可信区间，1.07-1.27；P
Context Neurotensin regulates both satiety and breast cancer growth in the experimental setting, but little is known about its role in the development of breast cancer or cardiometabolic disease in humans.Objective To test if fasting plasma concentration of a stable 117-amino acid fragment from the neurotensin precursor hormone proneurotensin is associated with development of diabetes mellitus, cardiovascular disease, breast cancer, and mortality.Design, Setting, and Participants Proneurotensin was measured in plasma from 4632 fasting participants of the population-based Malmo Diet and Cancer Study baseline examination 1991-1994. Multivariate Cox proportional hazards models were used to relate baseline proneurotensin to first events and death during long-term follow-up until January 2009, with median follow-up ranging from 13.2 to 15.7 years depending on the disease.Main Outcome Measures Incident diabetes mellitus, cardiovascular disease, breast cancer, and mortality.Results Overall, proneurotensin (hazard ratio [HR] per SD increment of log-transformed proneurotensin) was related to risk of incident diabetes (142 events; HR, 1.28; 95% CI, 1.09-1.50; P=.003), cardiovascular disease (519 events; HR, 1.17; 95% CI, 1.07-1.27; P